Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Carcinogenetic mechanisms of endocrine disruptors in female cancers (Review).
Del Pup L, Mantovani A, Cavaliere C, Facchini G, Luce A, Sperlongano P, Caraglia M, Berretta M. Del Pup L, et al. Among authors: caraglia m. Oncol Rep. 2016 Aug;36(2):603-12. doi: 10.3892/or.2016.4886. Epub 2016 Jun 21. Oncol Rep. 2016. PMID: 27349723 Free PMC article. Review.
The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL. Facchini G, et al. Among authors: caraglia m. J Exp Clin Cancer Res. 2007 Sep;26(3):307-12. J Exp Clin Cancer Res. 2007. PMID: 17987788 Clinical Trial.
New treatment approaches in renal cell carcinoma.
Facchini G, Perri F, Caraglia M, Pisano C, Striano S, Marra L, Fiore F, Aprea P, Pignata S, Iaffaioli RV. Facchini G, et al. Among authors: caraglia m. Anticancer Drugs. 2009 Nov;20(10):893-900. doi: 10.1097/CAD.0b013e32833123d4. Anticancer Drugs. 2009. PMID: 19752718 Review.
Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial.
Facchini G, Caraglia M, Morabito A, Marra M, Piccirillo MC, Bochicchio AM, Striano S, Marra L, Nasti G, Ferrari E, Leopardo D, Vitale G, Gentilini D, Tortoriello A, Catalano A, Budillon A, Perrone F, Iaffaioli RV. Facchini G, et al. Among authors: caraglia m. Cancer Biol Ther. 2010 Sep 15;10(6):543-8. doi: 10.4161/cbt.10.6.12611. Epub 2010 Sep 8. Cancer Biol Ther. 2010. PMID: 20657175 Clinical Trial.
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Correale P, Remondo C, Carbone SF, Ricci V, Migali C, Martellucci I, Licchetta A, Addeo R, Volterrani L, Gotti G, Rotundo MS, Tassone P, Sperlongano P, Abbruzzese A, Caraglia M, Tagliaferri P, Francini G. Correale P, et al. Among authors: caraglia m. Cancer Biol Ther. 2010 May 1;9(9):685-93. doi: 10.4161/cbt.9.9.11441. Cancer Biol Ther. 2010. PMID: 20697196 Clinical Trial.
529 results